Cipla Q1 profit drops 39% as North America weakness, margin compression overshadow record India sales

Cipla Ltd reported a 39% year-on-year decline in consolidated net profit for the June quarter, as weakness in its North American business and a sharp contraction in operating margins overshadowed record domestic sales.

The drugmaker's consolidated net profit fell to ₹789 crore in the first quarter of FY27 from ₹1,298 crore a year ago. Revenue from operations, however, rose 2.3% to ₹7,119 crore, while EBITDA declined 33% to ₹1,192 crore. EBITDA margin narrowed sharply to 16.7% from 25.6% in the year-ago period.

The subdued earnings weighed on investor sentiment, with Cipla shares falling as much as 3.46% to an intraday low of ₹1,366.10 on the NSE after the results were announced.

North America drags, India shines

The key drag during the quarter came from the North American business, where revenue declined 21% year-on-year to ₹1,532 crore (USD 162 million). The company, however, remains optimistic about a sequential recovery, supported by recent product launches and an expanding pipeline.

In contrast, Cipla's India business delivered its highest-ever quarterly revenue of ₹3,452 crore, registering a robust 12% year-on-year growth. The branded prescription business outperformed the Indian pharmaceutical market, while the chronic portfolio mix improved to 60.4%. Emerging Markets and Europe posted a 16% growth, while the One Africa business grew 12% during the quarter.

Higher costs squeeze margins

Despite the modest increase in revenue, profitability came under pressure due to higher operating costs. Employee benefit expenses rose to ₹1,497 crore from ₹1,312 crore a year earlier, while depreciation, impairment and amortisation expenses increased to ₹304 crore from ₹253 crore. Purchases of stock-in-trade also rose sharply year-on-year, contributing to the margin erosion. Tax expense, meanwhile, declined to ₹295 crore from ₹478 crore, indicating that the earnings decline was driven primarily by operating performance rather than taxation.

Management remains optimistic

"We are pleased to share that we continue to make considerable progress across our focused markets. In Q1FY27, we delivered global revenues of ₹7,119 crore. Our One-India business grew at a solid 12% year-on-year," said Achin Gupta, managing director and global CEO of Cipla.

Commenting on the outlook, Gupta said the company expects continued sequential growth in North America, supported by its upcoming product pipeline. He added that Cipla will continue to focus on expanding its key markets, strengthening flagship brands, investing in future products and pursuing regulatory resolutions.